Abstract
Objective. To characterize changes in the plasma metabolic profile in newly diagnosed rheumatoid arthritis (RA) patients upon commencement of conventional disease modifying anti-rheumatic drug (cDMARD) therapy. Methods. Plasma samples collected in an early RA randomized strategy study (NCT00920478) that compared clinical (DAS) disease activity assessment with musculoskeletal ultrasound assessment (MSUS) to drive treatment decisions were subjected to untargeted metabolomic analysis. Metabolic profiles were collected at pre- and 3 months post commencement of non-biologic cDMARD. Metabolites that changed in association with changes in the DAS44 score were identified at the 3 month timepoint. Results. A total of ten metabolites exhibited a clear correlation with reduction in DAS44 score following cDMARD commencement, particularly itaconate, its derived anhydride and a derivative of itaconate coA. Increasing itaconate correlated with improved DAS44 score and decreasing levels of CRP. Conclusion. cDMARD treatment effects invoke consistent changes in plasma detectable metabolites, that in turn implicate clinical disease activity with macrophages. Such changes inform RA pathogenesis and reveal for the first time a link between itaconate production and resolution of an inflammatory disease in humans. Quantitative metabolic biomarker based tests of clinical change in state are feasible and should be developed around the itaconate pathway.
Competing Interest Statement
RD, GB, KB, DP and MB have nothing to disclose. MM reports other support from CEREVANCE, LTD, outside the submitted work. AS reports grants from Pfizer UK, during the conduct of this survey. IM reports grants from Pfizer, grants from Chief Scientist Office, grants from ARUK, during the conduct of the study; grants and personal fees from BMS, personal fees from Abbvie, grants and personal fees from UCB, grants and personal fees from Pfizer, grants and personal fees from Janssen, personal fees from Lilly, outside the submitted work. JD reports grants from Chief Scientist's Office, Scottish Government and from Pfizer UK during the conduct of the study; non-financial support from Abbvie UK, outside the submitted work.
Clinical Trial
NCT00920478
Funding Statement
The TaSER study was jointly funded by a Clinical Academic Fellowship from the Chief Scientist?s Office, Scottish Executive and an Investigator Initiated project grant from Pfizer UK. The metabolomics study was funded by an additional Investigator Initiated project grant from Pfizer UK. RD was funded by Wellcome (105614/Z/14/Z). MPB is part of the Wellcome Centre for Molecular Parasitology funded by a core grant from Wellcome (104111/Z/14/Z).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Please contact the corresponding author in regards to accessing the experimental data.
